Division of Infectious Diseases and Immunology, Department of Microbiology, School of Medicine, Iwate Medical University, 1-1-1 Idaidori, Yahaba, Iwate, 028-3694, Japan.
Department of Microbiology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.
Sci Rep. 2021 Jun 3;11(1):11816. doi: 10.1038/s41598-021-91251-x.
Molecular mimicry is one of the main processes for producing autoantibodies during infections. Although some autoantibodies are associated with autoimmune diseases, the functions of many autoantibodies remain unknown. Previously, we reported that S16, a mouse (BALB/c) monoclonal antibody against the hemagglutinin-esterase fusion glycoprotein of influenza C virus, recognizes host proteins in some species of animals, but we could not succeed in identifying the proteins. In the present study, we found that S16 cross-reacted with acetyl-CoA acyltransferase 2 (ACAA2), which is expressed in the livers of BALB/c mice. ACAA2 was released into the serum after acetaminophen (APAP) administration, and its serum level correlated with serum alanine aminotransferase (ALT) activity. Furthermore, we observed that S16 injected into mice with APAP-induced hepatic injury prompted the formation of an immune complex between S16 and ACAA2 in the serum. The levels of serum ALT (p < 0.01) and necrotic areas in the liver (p < 0.01) were reduced in the S16-injected mice. These results suggest that S16 may have a mitigation function in response to APAP-induced hepatotoxicity. This study shows the therapeutic function of an autoantibody and suggests that an antibody against extracellular ACAA2 might be a candidate for treating APAP-induced hepatic injury.
分子模拟是感染过程中产生自身抗体的主要过程之一。虽然一些自身抗体与自身免疫性疾病有关,但许多自身抗体的功能仍然未知。以前,我们报道了 S16,一种针对丙型流感病毒血凝素-酯酶融合糖蛋白的小鼠(BALB/c)单克隆抗体,可识别某些动物物种中的宿主蛋白,但我们未能成功鉴定出这些蛋白。在本研究中,我们发现 S16 与乙酰辅酶 A 酰基转移酶 2(ACAA2)发生交叉反应,ACAA2 在 BALB/c 小鼠的肝脏中表达。在给予对乙酰氨基酚(APAP)后,ACAA2 释放到血清中,其血清水平与血清丙氨酸氨基转移酶(ALT)活性相关。此外,我们观察到在 APAP 诱导的肝损伤小鼠中注射 S16 后,S16 和 ACAA2 之间在血清中形成免疫复合物。注射 S16 的小鼠的血清 ALT 水平(p<0.01)和肝脏坏死区域(p<0.01)降低。这些结果表明 S16 可能对 APAP 诱导的肝毒性具有缓解作用。本研究显示了自身抗体的治疗功能,并表明针对细胞外 ACAA2 的抗体可能是治疗 APAP 诱导的肝损伤的候选药物。